We should always remember that drugs are produced for human beings, not for profit. As long as we stick to this belief, profits will follow.
——George W. Merck, founder of MSD
In July this year, the national pharmaceutical industry information annual conference released the "list of industrial enterprises in China's pharmaceutical R & D product line". Among more than 4700 pharmaceutical enterprises in China, Yabao pharmaceutical's R & D capacity ranked 11th, marking the domestic R & D capacity of Yabao pharmaceutical. As we all know, Yabao pharmaceutical is a leader in the field of pediatric drug production, with a large proportion of traditional Chinese medicine varieties in its original product line.
Why can an enterprise with specialized medicine advantages and traditional Chinese medicine gene rise rapidly in the field of innovation and R & D? Wang Peng, President of Yabao pharmaceutical Beijing Pharmaceutical Research Institute, interpreted this.
Large investment and more talents
In 2013, Professor Wang Peng, a distinguished expert of the "thousand talents plan" and a former scientist of the sound pharmaceutical industry, joined Yabao pharmaceutical and served as the president of Yabao Beijing Pharmaceutical Research Institute, which attracted extensive attention in the industry. In this regard, Wang Peng said: "Ren Wuxian, chairman of the board of directors, has given a very good positioning for scientific and technological innovation in Yabao's future strategy. That is to achieve the purpose of enterprise transformation and upgrading through two paths of new drug R & D innovation and internationalization, and develop China's traditional enterprises into international large-scale pharmaceutical enterprises, which is also the goal of the future development of China's entire pharmaceutical industry." It is precisely because he and chairman Ren Wuxian have a common pursuit and reached a consensus in the field of new drug R & D that they firmly chose Yabao. And aiming at the world's high-end market, we are determined to make truly world-class innovative drugs.
At that time, Yabao pharmaceutical had emerged in the industry because of its large investment in innovation. The company's annual investment in R & D accounted for 5% of the total sales revenue, which was much higher than the average value of 1.5% of the R & D investment of the whole domestic pharmaceutical industry. Few companies invested in new drug R & D in China.
Talent is the most critical element of new drug research and development. Yabao pharmaceutical has spared no effort in talent reserve and is ready to go. At present, Yabao pharmaceutical Beijing Pharmaceutical Research Institute has more than 200 professional R & D personnel. Among them, there are more than 150 masters, 26 doctors and postdoctors, including 8 doctors and postdoctors introduced from the United States, Britain, Japan and other countries. In addition, industry leaders such as Zeng Yi, academician of the Chinese Academy of Sciences, Hou Huimin, academician of the Chinese Academy of engineering, were invited to join Yabao to participate in enterprise independent innovation, and were identified as the first batch of overseas high-level talent innovation and entrepreneurship bases in Shanxi Province. In terms of new drug R & D and internationalization, the company has established a well-known R & D team with rich experience in the industry. It is reported that 16 domestic experts have recently joined Yabao "Shanxi Key Laboratory of transdermal drug delivery system". The joining of these experts has brought ideas, experience and technology to the company and integrated the resource advantages of domestic experts.
New mechanism of living mode
The most daunting aspect of innovative drug R & D is the average 10-year R & D cycle and the high risk caused by the investment of US $1 billion and low success rate. This is also the main reason why many pharmaceutical enterprise operators dare not expect innovative drugs. With many years of overseas study and working as a scientist in many multinational pharmaceutical enterprises, President Wang Peng has a very clear understanding of China's new drug R & D. He believes that drug research and development is divided into upstream, midstream and downstream. The upstream is very scientific. In view of the weak foundation of China's pharmaceutical industry, we can't copy the R & D path of multinational pharmaceutical enterprises. Chinese pharmaceutical enterprises must realize that in the early basic research and development dominated by science, China has a big gap and basically does not have this ability. The advantage of China lies in the clinical and market in the middle and late stage of R & D. The so-called combination of independent development and joint research and development now means that in the weakest link in the upstream, we all cooperate with foreign countries. The partners are all well-known multinational pharmaceutical companies and academic and scientific research institutions. We introduce foreign R & D projects that have been completed in the upstream in the form of joint development to do midstream and downstream in China, This is a very unique model in China. Since 2013, the company has signed 7 cooperation agreements with foreign well-known multinational pharmaceutical enterprises, international medical organizations and scientific research institutions such as Eli Lilly, the British Medical Research Institute, the University of South Australia and Rosen Health Research Institute in Canada, totaling 8 world innovative drug R & D projects. In September this year, a joint laboratory was established with the University of South Australia to extend the R & D platform overseas
It is understood that the R & D team headed by President Wang Peng is looking for international products all over the world. If it is a real innovative drug, once the target is locked, it will adopt a flexible cooperative way for joint development. The so-called joint development is to establish a real cooperative relationship with each other. The two sides jointly set up a team to complete the middle and lower reaches in China. From investment to benefit distribution, both sides are bound together, and both sides will obtain certain rights and interests, forming a model of sharing benefits and taking risks together. This is different from other domestic companies who spend money to buy projects from abroad. Foreign countries no longer participate in R & D and take the money to leave. This cooperation mode reduces the high risk of innovative drug research and development to a great extent. If the previous step is called import-oriented cooperation, the next step is called export-oriented cooperation. Now the company has eight cooperation projects, and each project needs to invest nearly 200 million funds. If these projects are launched at the same time, the company will face great pressure. President Wang Peng said that we have a good solution. It is impossible for the company to invest a huge amount of money in the short term to complete all the projects from beginning to end. Therefore, the mode now considered is to introduce the projects, do them for a period of time, and then find partners in China, including investors and other pharmaceutical enterprises. We can invest, do and share them together, Form an export-oriented mode of cooperation. This not only solves the problem of huge capital investment in the short term, but also promotes the trust and cooperation among enterprises in the domestic pharmaceutical industry.
Focus on clinical profit
Dr. Wang Peng said that George Merck, the founder of MSD, once had a wise saying: "we should always remember that drugs are produced for human beings, not for the pursuit of profits. As long as we stick to this belief, profits will follow". Yabao pharmaceutical believes in this proverb. Our innovative drugs are oriented to clinical needs and have high returns. Our principle is to do things successfully, regardless of how much returns we will get in the future. Therefore, we only focus on clinical needs rather than focusing on a certain field, let alone paying too much attention to corporate profits. In our research projects, there are new drugs for diabetes, new anticancer drugs, cardio cerebrovascular and septic drugs, and anti Parkinson's disease. It almost covers the most urgent needs of clinical practice, which makes our vision broader.
According to the schedule set by the company's new drug R & D investment, 2020 will usher in the peak of new drug listing. Under the background of domestic new drug registration and approval reform, the company is full of confidence in the timely listing of new drugs. President Wang Peng believes that the reform of new drug registration and approval, especially the redefinition of new drugs, the shortening of approval time for innovative drugs and the opening of green channels, are major favorable policies for the scientific research and development of Yabao pharmaceutical. Because the innovative drugs made by Yabao pharmaceutical are in line with the idea of encouraging innovation, it can be said that Yabao pharmaceutical has caught up with the good time of innovation. Wang Peng said that he would strive to launch heavy products at the end of the 13th five year plan and rank among the world's excellent enterprises.
请将简历发送至：